FWM
MRNA icon

FFT Wealth Management’s Moderna MRNA Stock Holding History

FFT Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-233
Closed -$55K – 187
2021
Q2 		$55K Buy
+233
New +$41.6K 0.01% 128

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

FFT Wealth Management's MRNA Position: Q3 2021 in Review

FFT Wealth Management sold out of Moderna (MRNA) in Q3 2021, closing a stake of 233 shares — an estimated $55K sold.

FFT Wealth Management first reported a position in MRNA in Q2 2021 and held it in 1 quarter. The position peaked at $55K in Q2 2021. 1,140 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

  • FFT Wealth Management reported no remaining Moderna position as of Q3 2021 after selling out during the quarter.
  • FFT Wealth Management sold 233 Moderna shares in Q3 2021, an estimated $55K.
  • FFT Wealth Management first reported a position in Moderna in Q2 2021 and held it in 1 quarter.
  • FFT Wealth Management's Moderna position peaked at $55K in Q2 2021.
  • 1,140 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on FFT Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.